Multi -Institutional Update on Salvage Radiation Therapy in Relapsed/Refractory Large B Cell Lymphoma Patients in Post-CART Cell Therapy Failure

被引：0
|
作者：
Ababneh, H. [1 ]
Ng, A. [2 ]
Frigault, M. J. [3 ]
Jacobson, C. [4 ]
Patel, C. G. [1 ]
机构：
[1] Harvard Med Sch, Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA USA
[2] Dana Farber Canc Inst, Boston, MA USA
[3] Harvard Med Sch, Massachusetts Gen Hosp, Boston, MA USA
[4] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA USA
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2024年 / 120卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
205
引用
收藏
页码：S66 / S67
页数：2
相关论文
共 50 条
  • [41] Safety and Efficacy of a DNA Oligonucleotide Therapy in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    Westin, Jason
    Maris, Michael B.
    Jacobson, Caron A.
    Patel, Prapti
    Lakhani, Nehal
    Harb, Wael
    Patel-Donnelly, Dipti
    McCaul, Kelly
    Escobar, Carolina
    Klencke, Barbara
    Al-Katib, Ayad M.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 (01): : 52 - 59
  • [42] Cellular therapy in older adults with relapsed/refractory diffuse large B-cell lymphoma
    Esteghamat, Naseem
    Tsumura, Aaron
    Marquez-Arreguin, Gabriel
    Tuscano, Joseph
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [43] Loncastuximab tesirine: an effective therapy for relapsed or refractory diffuse large B-cell lymphoma
    Xu, Bo
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2022, 78 (05) : 707 - 719
  • [44] The Impact of Bridging Therapy Prior to CAR-T Cell Therapy on Clinical Outcomes of Patients with Relapsed Refractory Large B-Cell Lymphoma
    Lutfi, Forat
    Kansagra, Ankit
    Ali, Moaath Mustafa
    Bukhari, Ali
    Siglin, Jonathan
    Yan, Jingsheng
    Samanta, Santanu
    Holtzman, Noa G.
    Gottlieb, David
    Kim, Dong Won
    Lee, Seung-Tae
    Kocoglu, Mehmet Hakan
    Yared, Jean A.
    Hardy, Nancy M.
    Molitoris, Jason
    Mohindra, Pranshu
    Rapoport, Aaron P.
    Dahiya, Saurabh
    BLOOD, 2020, 136
  • [45] Loncastuximab tesirine: an effective therapy for relapsed or refractory diffuse large B-cell lymphoma
    Bo Xu
    European Journal of Clinical Pharmacology, 2022, 78 : 707 - 719
  • [46] A paradox of choice: Sequencing therapy in relapsed/refractory diffuse large B-cell lymphoma
    Brooks, Taylor R.
    Caimi, Paolo F.
    BLOOD REVIEWS, 2024, 63
  • [47] Systematic Review of Therapy Used in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    Galaznik, Aaron
    Bell, Jill A.
    Hoog, Meredith M.
    Stokes, Michael E.
    Steenrod, Anna W.
    Knopf, Kevin B.
    Seal, Brian
    Shou, Yaping
    BLOOD, 2016, 128 (22)
  • [48] Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma
    Pinnix, Chelsea C.
    Gunther, Jillian R.
    Dabaja, Bouthaina S.
    Strati, Paolo
    Fang, Penny
    Hawkins, Misha C.
    Adkins, Sherry
    Westin, Jason
    Ahmed, Sairah
    Fayad, Luis
    Lee, Hun Ju
    Nair, Ranjit
    Steiner, Raphael E.
    Iyer, Swaminathan P.
    Rodriguez, M. Alma
    Wang, Michael
    Flowers, Christopher
    Neelapu, Sattva S.
    Nastoupil, Loretta J.
    BLOOD ADVANCES, 2020, 4 (13) : 2871 - 2883
  • [49] Challenges in Administering Salvage Therapy and Outcomes of Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients: A LMIC Real-World Study
    Charanpreet Singh
    Aditya Jandial
    Arihant Jain
    Deepesh Lad
    Alka Khadwal
    Rajender Basher
    Amanjit Bal
    Pankaj Malhotra
    Gaurav Prakash
    Indian Journal of Hematology and Blood Transfusion, 2024, 40 : 231 - 236
  • [50] Challenges in Administering Salvage Therapy and Outcomes of Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients: A LMIC Real-World Study
    Singh, Charanpreet
    Jandial, Aditya
    Jain, Arihant
    Lad, Deepesh
    Khadwal, Alka
    Basher, Rajender
    Bal, Amanjit
    Malhotra, Pankaj
    Prakash, Gaurav
    INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION, 2024, 40 (02) : 231 - 236
12345